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Experiences of caregivers of children with
inherited metabolic diseases: a qualitative
study
Shabnaz Siddiq1, Brenda J. Wilson1, Ian D. Graham1,2, Monica Lamoureux3, Sara D. Khangura1, Kylie Tingley1,
Laure Tessier3, Pranesh Chakraborty3, Doug Coyle1, Sarah Dyack4, Jane Gillis5, Cheryl Greenberg6,
Robin Z. Hayeems7,8, Shailly Jain-Ghai9, Jonathan B. Kronick10, Anne-Marie Laberge11, Julian Little1,
John J. Mitchell12, Chitra Prasad13, Komudi Siriwardena9, Rebecca Sparkes14, Kathy N. Speechley15, Sylvia Stockler5,
Yannis Trakadis12, Sarah Wafa12, Jagdeep Walia16, Kumanan Wilson1,2, Nataliya Yuskiv5, Beth K. Potter1* on behalf
of the Canadian Inherited Metabolic Diseases Research Network (CIMDRN)

Abstract
Background: We sought to understand the experiences of parents/caregivers of children with inherited metabolic
diseases (IMD) in order to inform strategies for supporting patients and their families. We investigated their experiences
regarding the management of disease, its impact on child and family life, and interactions with the health care system.
Methods: From four Canadian centres, we conducted semi-structured telephone interviews with parents/caregivers of
children with an IMD who were born between 2006 and 2015 and who were participating in a larger cohort study.
Participants were selected with the aim of achieving a diverse sample with respect to treatment centre, IMD, and age
of the child. Interviews emphasized the impacts of the disease and its treatment on the child and family and explicitly
queried perceptions of interactions with the health care system. We identified emergent themes from the interview
data.
Results: We completed interviews with 21 parents/caregivers. The 21 children were aged <1 to 7 years old with IMD
that included amino acid disorders, urea cycle disorders, fatty acid oxidation disorders, and organic acid disorders or
‘other’ IMD. Most parents reported that they and their families had adapted well to their child’s diagnosis. Parents used
proactive coping strategies to integrate complex disease management protocols into routine family life. An important
source of stress was concern about the social challenges faced by their children. Participants reported positive
interactions with their most involved health care providers within the metabolic clinic. However, they reported
challenges associated with the health care system outside of disease-specific metabolic care, when encountering
systems and providers unfamiliar with the child’s disease.
Conclusions: The successful use of proactive coping strategies among parents of children with IMD in this study
suggests the potential value of promoting positive coping and is an important direction for future study. Parents’ social
concerns for their children were important stressors that warrant consideration by health care providers positioned to
support families. Our results with respect to experiences with care highlight the important role of specialized metabolic
clinics and point to a need for better coordination of the care that takes place outside the disease-specific
management of IMD.
Keywords: Experiences with care, Inherited metabolic diseases, Family support, Coping, Qualitative research
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Background
Inherited metabolic diseases (IMD) are a large group
of individually rare single gene disorders, most often
diagnosed early in life, that involve defects in metabolic pathways. They are characterized by a range of
clinical manifestations that can include episodes of acute
metabolic crises, insidious manifestations, or chronic
multi-systemic sequelae [1]. Advancements in medical
interventions have increased life and health expectancy in
individuals with IMD, with new therapies appearing at an
accelerating pace [2]. However, both disease manifestations and treatment regimens, which frequently involve
highly specialized diets and medications, may be important sources of stress and have important impacts on quality of child and family life [3–7] and on the health care
system [8].
Research to describe families’ perspectives and experiences in caring for children with IMD, both at home
and when receiving care, can help clinical- and systemlevel providers to better understand how to optimize
their support of children with IMD and their caregivers.
In this qualitative interview study, we aimed to understand parents' experiences with the management of
their child's IMD, the impact of the disease and its
management on child and family life, and their perceptions about their interactions with the health care
system.
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telephone or email. Participants provided written informed consent prior to the interview. A maximum of
three attempts were made to contact families, a voice
message being left with each contact where possible. If
no response was forthcoming or the family declined
participation, no further contact was made.
Data collection

Telephone interviews were conducted by a single researcher (SSi) using a semi-structured interview guide.
The interview guide was informed by a broad scoping review of the literature [14] and revised through discussion
among investigators with expertise in qualitative methods
and clinical experience in treating IMD. Topics covered
by the guide included well-being (mental, physical and social health) of the child and family, experiences with daily
disease management at home, and interactions with the
health care system, including diagnostic care and care associated with on-going disease management. A pre-test of
the interview guide was conducted with a parent of a child
with an IMD who was an advisor to the study team; data
from the pre-test interview were not included in the
analysis for the final study. All interviews were audiorecorded with participants’ consent and subsequently
transcribed.
Analysis

Methods
Participants

This study was embedded in a larger, multi-faceted
cohort study as part of the Canadian Inherited Metabolic
Diseases Research Network (CIMDRN) [9]. CIMDRN is
a pan-Canadian multi-disciplinary network that has established a consent-based cohort of >550 children, born between 2006 through 2015, diagnosed with one of 31 IMD
(Table 1), and receiving care at one of 13 participating
pediatric metabolic clinics. Eligible participants for the
present study were parents/guardians of children enrolled
in CIMDRN’s cohort study at one of four of these participating metabolic clinics (in Halifax, Montreal, Ottawa,
and Vancouver, Canada) who had consented to be contacted to participate in an interview and/or survey. The
selected participants were nominated by their families as
the most knowledgeable of the child's disease and care.
From the CIMDRN cohort at the four centres listed
above, for the present study we used a purposive sampling method to achieve a sample of parents/guardians
that represented a diverse group of children receiving
care at different centres, with different IMD, and of different ages [10]. The eventual sample size was dependent on
data saturation [11]. Based on previous experience and
published guidance [12, 13], we anticipated approximately
15-25 interviews. Selected eligible families were invited by

Seven members of the research team collaborated on an
initial thematic analysis of the first three interview transcripts [15, 16], to identify broad categories and codes and
to revise the interview guide. One researcher (SSi) coded
all subsequent interviews, with review and verification by
a second researcher (BKP). Analysis took place concurrently with the interview process so that emergent themes
could be incorporated into subsequent interviews [17].
Discussions among team members were held regularly to
review the transcripts, discuss emerging themes, assess
the degree of saturation, and identify priorities for participant recruitment. We actively sought negative examples
during the analysis of the data, i.e., findings that were inconsistent with the overall results that were emerging
from the study. This was made possible through querying
emerging themes in subsequent interviews. The analysis
was supported by NVivo software (http://www.qsrinternational.com). Participants who consented to be recontacted for this purpose received a preliminary summary of the study findings and were invited to submit any
questions or comments to the investigators.
Ethics approval for this study was received from the
Children's Hospital of Eastern Ontario Research Ethics
Board, the Ottawa Health Science Network Research Ethics Board, the University of British Columbia/Children's
and Women's Health Centre of British Columbia Research
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Ethics Board, and the McGill University Health
Centre Research Ethics Board.

Results
From 36 recruitment invitations, 21 caregivers provided
signed informed consent and completed an interview.
Even though data saturation with respect to main themes
was judged to have been achieved with 13 interviews, we
continued to interview all participants who had provided
consent, to incorporate their views in recognition of their
interest in the study, in order to enrich the data as much
as possible across the diverse set of diseases involved, and
because of the limited literature on family experiences
with IMD.
Most participants (n = 18) were mothers of the child
with an IMD (the other three participants were fathers or
grandparents). Twelve different diseases were represented
(Table 1); for the purposes of reporting and to protect the
identity of families with these rare conditions, we categorized these as amino acid disorders, urea cycle disorders,
fatty acid oxidation disorders, and organic acid disorders
or ‘other’ IMD, when labelling participant quotations. The
age of the children whose parents were interviewed
ranged from under 1 year to 7 years. The vast majority of
the children of participants (n = 17) were diagnosed with
an IMD very early in life, through newborn screening programs. The average interview length was 55 min. Of participants who received a preliminary summary of the
findings (n = 18), none provided comments or questions.
Participants’ descriptions of their children’s symptoms
and management protocols were heterogeneous. Despite
this, we identified key themes related to families’ experiences that were strikingly cross-cutting. We report the key
emergent themes within the two broad topics on which
the interviews focused: experiences with disease and its
management at home and in the community and experiences with the health care system.
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Table 1 Eligible IMD (12 of these 31 diseases were represented
in this interview study, shown in italics, with multiple interviews
for some diseases)
Amino acid disorders:
Phenylalanine hydroxylase deficiency
Homocystinuria
Maple syrup urine disease
Tyrosinemia Type I
Urea cycle disorders:
Arginase deficiency
Argininosuccinic acidemia
Carbamyl phosphate synthetase deficiency
Citrin deficiency
Citrullinemia
Hyperornithinemia-Hyperammonemia-Homocitrullinuria syndrome
N-acetylglutamate synthetase deficiency
Ornithine transcarbamylase deficiency
Fatty acid oxidation disorders:
Medium chain acyl-CoA dehydrogenase deficiency
Very long-chain acyl-CoA dehydrogenase deficiency
Carnitine uptake defect
Long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency
Trifunctional protein deficiency
Organic acid disorders or ‘other’ IMD:
ß-Ketothiolase deficiency
Glutaric acidemia type I
HMG-CoA lyase Deficiency
Isovaleric acidemia
3-Methylcrotonyl-CoA carboxylase deficiency
Methylmalonic acidemias
Propionic acidemia
Guanidinoacetate methyltransferase deficiency
Mucopolysaccharidosis type I
Farber disease

Experiences with disease and its management at home
and in the community

We organized the results under three key themes: (i) the
‘new normal’ and proactive coping; (ii) social stressors;
and (iii) parent advocacy.
(i) The ‘new normal’ and proactive coping
The daily management of their child's IMD was described by many caregivers as intense, due to the need
for the child (and sometimes the entire family) to learn
to adhere to very restricted diets and treatment regimens. For example, many parents expressed difficulties
associated with the early stages of adjusting to disease
management:

Galactosemia
Glycogen storage disease type 1
Multiple carboxylase/biotinidase deficiency
Pyridoxine-dependent epilepsy

"…it was a really big adjustment for our family just
learning new ways, like new ways of eating I guess,
because we were not, we're not vegetarians."
(participant 11, amino acid disorder)
"I would say the worst of it was when he was a
newborn because they told us that we had to feed
him exactly every 3 h." (participant 18, fatty acid
oxidation disorder)
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Some parents took a leave of absence or even sacrificed
their careers to learn and adapt to the complexities of the
disease:
"I never went back to work. I was a [occupation] and
made more money than my husband. I gave up my job
to take care of [child]...." (participant 10, organic acid
disorder or other IMD)
"I took an extra year off just to make sure that I
understood her diet properly and to make sure that I
found a daycare that's going to be convenient."
(participant 11, amino acid disorder)
However, participants often reported that they eventually adjusted well to the complex day-to-day management,
so that it became the 'new normal' for their family:
"We don't know anything else… it keeps the family on
a very strict routine because we know we have to get
that breakfast, lunch and dinner into them. So, it's a
very timetabled thing." (participant 04, amino acid
disorder)
"But we have no choice…they're going to have to deal
with that all their life and…they don't know any
better…some people tell us we're lucky because we
haven't had a kid that doesn't have it, so we don't know
how it is like, how easy it would be if they wouldn't have
[disease]." (participant 17, amino acid disorder)
Indeed, some participants expressed that it was challenging to consider how the disease impacted their family life,
since it was now all they knew:
"Nowadays it's one of my routines. I know what he
has…it's very simple for me right now, I know how to
calculate and everything… We're so used to it you
know?" (participant 16, amino acid disorder)
"We live in a new version of normal that is a
heightened level of stress so… we live in the state of
stress, it's just our new normal so I don't know that we
notice it as much. It doesn't go away so it's just always
there right?" (participant 15, amino acid disorder)
This adjustment to life with an IMD seemed to be
accomplished through the use of a range of coping
strategies. Specifically, respondents provided numerous
examples of the organization, planning, and lifestyle
changes they had undertaken in order to cope with disease management and establish routines. For example,
for one family this included a choice to live close to the
child's school:
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“We are living in apartment in [area] and just a few
steps from school…very close to the school just in case
anything happened we can go to the school.”
(participant 06, organic acid disorder or other IMD)
For other families, it included selectively placing the
child in a specific supportive day care or school:
"I drive 20 min of out my way…of where I work
and live just so I can take them there [child's
daycare]. I think, you know, I trust them so, you
know and they're really good with the kids and it's
a family-run daycare…" (participant 07, fatty
oxidation disorder)
Planning ahead and being prepared for meals was
described as important by several participants, for
example:
"We do basically 2 trips to the grocery store every
week, and everything is planned on a 7 day calendar…
Friday, Saturday I'll sit down and I'll plan out the
meals for the week." (participant 21, fatty acid
oxidation disorder)
Organizing support from extended family members
was another strategy mentioned by several participants:
"…both our moms have the scale at their house, they
have food for her. And then, we are hoping to go
[State] in Spring break so my mom is gonna come
along just to help us out." (participant 03, amino acid
disorder)
"Our social life is pretty good because now we can
drop him off at my in-laws, or my parents and we can
go out, we can have a life." (participant 10, organic
acid disorder or other IMD)
Parents also used social media and the internet for
accessing information and resources and for connecting
with other families:
"…the only thing is the support group on Facebook so if
I have questions or whatnot it… it is nice to be able to
go on there and get experiences from other parents."
(participant 11, amino acid disorder)
"…for the first little while it was mainly just researching
it on the internet…" (participant 09, fatty acid oxidation
disorder)
For many families, vacations were described as requiring a lot of planning and preorganization:
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"…you kind of have to visualize what you're going to
do…what you need to pack because it's not just
packing your clothes, we have to pack all the food, we
have to bring their bread we have to… So that's a
challenge." (participant 17, amino acid disorder)
Another respondent described developing a spreadsheet
to manage health care appointments:
"I created a spreadsheet of all of our specialists, all the
tests we have to do, so it's, you know it's an ongoing
spreadsheet that I update… every 3, 4 months and the
nice thing about it is that when I do update it…which is
a lot of work but when I…do it then I know what I'm
missing." (participant 10, organic acid disorder or
other IMD)
(ii)Social stressors
Despite these coping strategies and the sense that
many families were coping well, participants often
reported feeling stress related to concerns about
the social lives of their children, particularly
surrounding situations where the child may be
excluded because of necessary dietary restrictions.
These challenges intensified during holidays and
special events:
"…just going to children's birthday parties or things like
that, it is getting a bit more difficult… she sees them
eating this food, and then she'll look at hers and she
knows that it's not the same right? Yeah so it is very,
it is difficult…" (participant 11, amino acid disorder)
Some parents/guardians described experiencing difficulties accessing special medical foods that are
similar to foods eaten by unaffected children. Being
able to identify with other children in this way was
depicted as important for the social development of
the child:
“…but normality, being able to find something
comparable to what all the other kids are eating,
that's been a huge pain…She gets a little sulky
sometimes, because she knows she is not getting
exactly the same thing the kids get but we go out of
our way to find kind of like the replica…”
(participant 01, organic acid disorder or other IMD)
Feeling isolated or excluded was identified by some parents as a particular worry for their child while at school:
“… when the food comes in the teachers tend to give
them a pencil or an eraser and we have now a bucket-
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full of pencils and erasers and that is a measurement
of how often that they are left out of these things…”
(participant 04, amino acid disorder)
(iii)Parental advocacy
Perhaps in part as a response to social challenges,
a third theme, parental advocacy, emerged when
considering children's access to special services and
inclusion in activities, particularly in the context of
managing the diet, which required parental vigilance
in order to prevent a child’s exposure to restricted
foods:
"…we just have to really advocate for her. We are part
of a church, and our church in the infant nursery like
would provide [brand name] crackers for kids and like
she can't have [brand name] crackers and I didn't
want them to handing out food so just kind of
suggesting that they change the way they do things."
(participant 03, amino acid disorder)
"We have [activity club for children] and the
reason why I became a Unit Leader was because I
needed to push the food out of weekly meetings
because it was something, again, [child] would be
exposed to it during the day." (participant 04,
amino acid disorder)
Some caregivers also described advocating on a broader
level, with the government, in order to access needed
foods or services:
"…the only complaint I have about that is we…so we
lobbied the [Provincial government]… we met with our
[political representative] and we petitioned for
coverage of low protein foods…." (participant 15, amino
acid disorder)
The rarity of IMD was sometimes perceived to necessitate parental advocacy in school settings:
"…because the school board has never dealt with a
child that has [disease]…I went in there with an 8
page letter…I kept telling the school board, if my son
doesn't get the amount of hours that I requested, he
will not go to your school." (participant 10, organic
acid disorder or other IMD).

Experiences with the health care system

The two key themes that emerged within this broad
topic were: (i) experiences with IMD-specific care; and
(ii) experiences with non IMD-specific care.
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(i) Experiences with IMD-specific care
Parents commonly reported that children required frequent health care interactions involving multiple providers
from various disciplines. Almost all of the children in this
study received disease-specific care from specialist metabolic physicians and dietitians. Most participants were
highly satisfied with the care that their child received in
the specialist metabolic clinic, with metabolic health care
providers regarded as supportive, and dietitians in particular described as highly engaged with families:
“…when we finally met [metabolic physician] … he
gave us the time. At no time did we ever feel that we…
needed to hurry up and get out and we were extremely
happy.” (participant 13, fatty acid oxidation disorder)
“…the dietitians really help, like really help a lot, you
know, um, really guiding me and everything with his
intake with food and you know, trying new things.”
(participant 08, amino acid disorder)
“… there was one person that changed our life
throughout the whole process and that was [name of
dietitian]…She was life-changing. Whoever is in her
position is life-changing for someone in our position. She
was incredible because she spoke to us in a way that we
didn’t feel like we were going to end the world with
certain decisions… she very much helped to relax us a
little bit and to feel normal, like helping us to cope with
our new normal.” (participant 05, urea cycle disorder)
Respondents also commonly expressed satisfaction
with the coordination of care in this part of the health
care system:
"Oh, when she was diagnosed it was great because
[metabolic physician] and [dietitian] would come in
together and we got a chance to see both. We have an
option to see them separately. So yah, there is
definitely a good coordination between them."
(participant 01, organic acid disorder or other IMD)
"I find the [metabolic clinic] to be really well, really
effective, really coordinated and great systems in
[children's hospital] so that part has been really great."
(participant 15, amino acid disorder)
(ii)Experiences with non IMD-specific care
Although respondents expressed contentment with
IMD-specific care, many participants reported negative
experiences and dissatisfaction with non IMD-specific
components of the health care system that were used
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frequently by their child, for example, the emergency department, the pharmacy, or the blood laboratory; and
with coordination among these components of care.
For many children, frequent blood draws were required and were described as highly stressful due to the
inherent pain:
“There was a time we took [child] for a blood draw
and I could hear her, and I could hear her screaming
and [technician] was fishing in [child]'s arm for the
vein. Like, excessively fishing and I asked her to stop.
Blood draws were very, very difficult." (participant 05,
urea cycle disorder).
Some parents expressed their concerns about the specific services in phlebotomy, including access to highly
experienced professionals, late results, or inconvenient
hours:
"…my son is very small…They have to take a lot of
blood. And the people, I don't think they have enough
experience to poke a child so young....there's another
team for the just for the young…But we cannot access
to this team." (participant 14, urea cycle disorder)
"…we do it at home with the finger. I receive the blood
work of my son not on the second day, not on the
third, later, so I don't know what's going on like, this
week, my son could have the level very high for 1 week
and I'm not gonna know, and the next week I'm going
to receive the results." (participant 12, amino acid
disorder).
"…having a clinic open Saturday mornings for even
just one hour because we do blood work so regularly…
it impacts a lot of people's schedules… eat up a lot of
our vacation time, sick leave, parental leave, whatever
we have… just for the blood work alone." (participant
04, amino acid disorder).
Respondents also discussed challenges related to the
internal coordination of the hospital. For example, this
included concerns with receiving the correct medication
from the pharmacy and access to special medical foods
when the child was a hospital inpatient:
"…we were told not to use medication from home …
but the pharmacy, when she was in emerg that
afternoon, they were going to send up her meds from
pharmacy, which they didn't…So we gave her the meds
that we already had, in which case they said – Don’t
use the meds you have from home. Well, we didn’t
hear from pharmacy again until the next morning."
(participant 05, urea cycle disorder)
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"…but they didn't have any soy based formula at all.
And we have since had her in the hospital as she got
older but we don't let her eat anything from the
hospital because there is always something in it that
she can't eat." (participant 01, organic acid disorder or
other IMD).
However, there were exceptions, with a small number of
participants reporting positive experiences with the internal coordination of hospital departments. For example,
one participant reported that their child’s special dietary
needs were communicated well upon hospital admission
and noted that the family appreciated the opportunity to
bring and refrigerate foods from home:
“Yeah we’ve never had an issue and in most cases the
floor knows we’re coming up…and so the low fat menu
is already in our room…. it’s been very smooth, I mean
we all… once we’re admitted whoever goes home to
shower or change or grab extra things…brings back
some of her familiar snacks and there’s always a fridge
in the room so we fill it…” (participant 21, fatty acid
oxidation disorder)
A second participant who was satisfied with care coordination attributed this in part to the family’s personal
efforts to become involved in hospital activities and
show their appreciation; and in part to the metabolic
physician’s role in coordinating with other departments:
“…We have had a need to kind of cross over into
other departments…and we’ve found them to be all
very supportive and helpful … part of it though is a
bit self-created …we really try and reach out to
them…when we walk into the hospital…everybody is
excited to see [child], everyone knows who [child] is…
we have great things to say but we work hard to make
sure those relationships are there” (participant 15,
amino acid disorder)
“…Our [metabolic physician] is really good at…making
sure she’s up to date…on what those results from the
other departments were and.. she has good relationships
within the hospital.. again but it’s a person-dependent
scenario…if you have a doctor who … nobody likes or if
you have a doctor that is shy or not well connected, well
then maybe my experience would be different….”
(participant 15, amino acid disorder)
Concerns about the care their child received in the
emergency department was noted by several participants.
Respondents commonly expressed their distress and dissatisfaction with the inconsistency in care received from
the emergency department during a crisis:
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"… I just have a lot of stress around mostly around the
health care that we received there [emergency
department] because I can't say that it's consistent at
all…I feel like almost like I have to prove that they are
sick…" (participant 02, fatty acid oxidation disorder)
This sometimes extended to worry about the capability
of emergency professionals to manage the needs of patients
with a rare (and unfamiliar to the provider) condition:
"When we go to the ER in crisis…we know what to say,
we know what's going to work… we've come up against
a couple of doctors in the ER that don't appreciate
that, they want to be the ones to… when they walk
into the room, everyone looks to them for the answers."
(participant 21, fatty acid oxidation disorder)
In contrast, a small number of participants described
having positive experiences and expressed satisfaction
with the care their child received at the emergency
department. In one case, this was attributed to a letter
provided to the parents by the metabolic specialist
clinic, to inform emergency providers about the
illness:
“…so we just took him right to emergency, and what
helped is that they gave us a letter that said that he
can have a metabolic crisis…so as soon as I checked in
to the pediatric emergency, I gave them the letter and
explained that it’s… you know… quite serious…And
they got us in right away.” (participant 18, fatty acid
oxidation disorder)
However, another participant described an experience
whereby the emergency letter was not taken seriously by
a provider:
“…the first time I had to bring [child] in with the
protocol letter, the guy who’s a male nurse … he looked
at it and he says, ‘What’s this?’ And I said, ‘It’s a
protocol letter. I was told to give you that before I even
handed over the (insurance card)’…He goes, ‘Well who
is this… this doctor?’…and he was making fun of it
there and he tossed the paper.” (participant 13, fatty
acid oxidation disorder)
In summary, participants often felt comfortable with
the management of the major clinical manifestations of
their child’s condition but expressed frustration with
frequently used services outside of the specialist clinic.
While these frustrations were often relayed as single
anecdotal experiences, parents emphasized their importance as sources of stress that impacted quality of
life. As one parent noted:
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“…quite often it’s very, very small things that make a
massive difference in overall patient care.” (participant
05, urea cycle disorder)

Discussion
Parents of children with IMD in this study reported that
they became well-adjusted to the complex daily management requirements of their child's disease and redefined
their ‘new normal’ through the use of proactive coping
strategies. Despite these coping strategies, many respondents reported stress related to concerns about the social
lives of their children that necessitated parent advocacy,
particularly surrounding situations where the child may
be excluded because of dietary restrictions. Most parents
interviewed were highly satisfied with care received in
the specialist metabolic clinic. However, they often reported negative experiences with the non IMD-specific
components of the health care system that their children
used frequently. While these were often described to the
interviewer as stories about single events, they were
recounted across many interviews and parents reported
these experiences as an important source of stress.
Our findings with respect to coping and the importance
of social support and social challenges are supported by
the small body of literature related to family experiences
among children with an IMD. Parents of children with an
IMD have been reported in other studies to adjust well to
their child’s diagnosis [18–20], although the impact of
IMD on parent and family well-being may depend on the
specific disease and its manifestations [21]. Proactive coping or future-oriented thinking includes a set of strategies
that involve anticipating probable risks and stressors that
may cause harm and taking actions beforehand to prevent
or reduce their impact [22, 23]. Previous research in this
area has identified parents’ use of a range of strategies that
included proactive coping, other positive coping strategies
(e.g., religion, emotional/social support), and less adaptive
means of coping (such as substance use) [24]. Similar to
our study, others have identified social support, including
close family and friend relationships [5, 20, 25, 26] and social media [27], as important to caregiver and family wellbeing. These informal support systems were commonly
identified as important in our study, while the receipt of
formal psychological or counselling services was mentioned less frequently by participants. To the extent that
positive coping strategies may be associated with higher
quality of life for the child and family, coping is a promising area for further research and potential supportive
interventions.
Families’ concerns about the social development of
children with IMD may be exacerbated during life transitions, particularly adolescence [25, 27], and may be
more prevalent for IMD characterized by significant
physical disability [25]. In our study we identified social
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challenges in families of relatively young children (up
to age 7) that were mainly connected to the need for
specialized diets, and thus we were unable to corroborate previous research about transitions to adolescence
and adulthood. However, the persistence of these concerns about social development in studies of pediatric
IMD strongly suggests a need to address children’s social needs alongside social support for parents. Indeed,
recent qualitative studies found that for children with
mucopolysaccharidoses and their families, concerns
about ‘fitting in’ with peers and within broader society
were dominant themes [28, 29]. Parent advocacy was
an important theme that emerged in our study in part
in relation to the social challenges described above and
also extended to advocacy around access to care. We
did not identify advocacy as a theme in related IMD literature. While we did not collect socioeconomic data
for our study sample, the parents we interviewed may
have been relatively socioeconomically advantaged,
which may have afforded them greater resources and
capacity to participate in advocacy activities. Supporting this possibility, a common parent-reported theme
in the literature but not in our study is financial stress
[6, 7, 21, 30, 31].
To our knowledge, ours is the first study to specifically describe differences in families’ experiences with
disease-specific and non-disease-specific health care
services for IMD. Previous studies have identified both
positive and negative care experiences in this population
[7, 31] and one previous study specifically identified challenges with care from providers unfamiliar with a child’s
conditions (e.g., in the emergency department) [7]. Guidance for providing care for children with special needs
suggests some potential strategies for addressing these
challenges – for example, co-developed care plans, receipt
of care within a ‘Medical Home’, relational continuity with
a single key provider, facilitating collaboration across providers, and increasing family involvement as full partners
in the care of their child, including health care decisionmaking [32–36]. Further research is needed to identify
which specific strategies may best address the needs of
children with IMD. Such research will be critical to help
IMD centres develop effective approaches to communication with providers and systems both within and outside
the metabolic clinic, for example, in order to: facilitate appropriate emergency management of metabolic crises in
children with IMD; ensure that both health care providers
and school-based professionals are aware of and support
the special dietary and medication needs associated with
IMD management; and identify approaches to improve
the experiences of families who are frequent users of services such as phlebotomy.
Important strengths of this study include its wide representation of IMD and its in-depth insights generated
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about families’ experiences, both with home management
and with receipt of health care. A further strength was our
use of several strategies to ensure the rigour of the
methods and verify the findings to enhance their credibility [37]. These strategies included participation of multiple
investigators in reviewing the interview data, analyzing the
data in parallel with the conduct of the interviews so that
emerging results could be investigated in later interviews,
and actively seeking and discussing negative examples i.e.,
findings that that were inconsistent with the overall emerging results, during the analysis.
A limitation of our study is that the small number of
families with experience of any single IMD, or any single set of disease manifestations or treatment protocols,
precluded us from fully investigating differences across
disease characteristics. Previous research has identified
differences in quality of life among parents of children
with different IMD [21]. As well, other studies have
identified diagnostic delays as a source of stress for
families with IMD. Since the vast majority of children
of our study participants were diagnosed through newborn screening, we had insufficient data to reflect upon
this particular challenge, which deserves further study
in future research involving children with rare diseases
not identified within the first few weeks of life [30].
Furthermore, although we completed interviews with
58% (21/36) of families who were invited to participate
in the study, those who did not participate may have
been experiencing more challenges in coping, and thus
were unable to devote time to participating in an hourlong telephone interview. Our findings thus warrant
additional investigation in samples that are representative
of the full population. Understanding the perspectives of
families experiencing the highest intensity of stress, with
respect to both needs and availability of resources, will be
particularly challenging. This may require less burdensome methods of data collection to facilitate participation
in research, for example, short surveys or brief in-clinic interviews. Such studies could also strive to incorporate validated measures of the psychosocial factors we identified
as priorities, for example, coping and social support, to
further elucidate families’ experiences and to investigate
their association with quality of life. Future studies could
also seek to better understand fathers’ experiences, given
that most participants in our study were mothers. Finally,
there is a need for research that emphasizes children’s
own perspectives, particularly through adolescence and
the transition to adult health care systems.

Conclusion
The successful use of a range of proactive coping strategies among parents of children with IMD in this study
suggests the potential value of promoting their use and
is an important direction for future study. Parents’ social
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concerns for their children were important stressors that
warrant consideration by health care providers positioned
to support families. Our results with respect to experiences with care point to a need to better coordinate care
across the entire health care system, including those components that are not specific to the management of IMD.
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